<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="int-interactant" /><meta name="keywords" content="" /><title>Antimalarials: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="41001i334.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="41001i334.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=41001i334.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="41001.htm">Appendix 1 Interactions</a> &gt; <a href="53178.htm">List of drug interactions</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="41001i325.htm" title="Previous: Promethazine">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="41001i937.htm" title="Next: Artemether with Lumefantrine">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_41001i334">Antimalarials</h1><div id="pC" class="jN"><p class="int-specific-drug-name"><b>Antimalarials</b>
          has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody><tr><td><a href="41001i937.htm" name="_937">Artemether with Lumefantrine</a></td><td class="cBV"><b>avoidance of  antimalarials advised by manufacturer of artemether/lumefantrine </b></td><td></td></tr><tr><td><a href="41001i1180.htm" name="_1180">Histamine</a></td><td>avoidance of  antimalarials advised by manufacturer of histamine </td><td></td></tr><tr><td><a href="41001i1058.htm" name="_1058">Typhoid Vaccine (oral)</a></td><td> antimalarials inactivate oral typhoid vaccine—see under Typhoid vaccines, <a title="monograph-family: Typhoid vaccines" href="6528.htm#_6528">section 14.4</a></td><td></td></tr></tbody></table><p><b>Artemether with Lumefantrine</b> belongs to
      <b>Antimalarials</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

























<tr><td><a href="41001i118.htm">Amiodarone</a></td><td class="cBV"><b>manufacturer of  artemether/lumefantrine advises avoid concomitant use with amiodarone (risk of ventricular arrhythmias)</b></td><td>Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</td></tr><tr><td><a href="41001i229.htm">Antidepressants</a></td><td class="cBV"><b>manufacturer of  artemether/lumefantrine advises avoid concomitant use with antidepressants </b></td><td></td></tr><tr><td><a href="41001i293.htm">Antifungals, Imidazole</a></td><td class="cBV"><b>manufacturer of  artemether/lumefantrine advises avoid concomitant use with imidazoles </b></td><td></td></tr><tr><td><a href="41001i300.htm">Antifungals, Triazole</a></td><td class="cBV"><b>manufacturer of  artemether/lumefantrine advises avoid concomitant use with triazoles </b></td><td></td></tr><tr><td><a href="41001i334.htm">Antimalarials</a></td><td class="cBV"><b>manufacturer of  artemether/lumefantrine advises avoid concomitant use with antimalarials </b></td><td></td></tr><tr><td><a href="41001i363.htm">Antipsychotics</a></td><td class="cBV"><b>manufacturer of  artemether/lumefantrine advises avoid concomitant use with antipsychotics </b></td><td>Increased risk of toxicity with myelosuppressive drugs</td></tr><tr><td><a href="41001i1005.htm">Atazanavir</a></td><td>manufacturer of  artemether/lumefantrine advises caution with atazanavir </td><td></td></tr><tr><td><a href="41001i1214.htm">Boceprevir</a></td><td class="cBV"><b>avoidance of  artemether/lumefantrine advised by manufacturer of boceprevir </b></td><td></td></tr><tr><td><a href="41001i744.htm">Cimetidine</a></td><td class="cBV"><b>manufacturer of  artemether/lumefantrine advises avoid concomitant use with cimetidine </b></td><td></td></tr><tr><td><a href="41001i1091.htm">Darunavir</a></td><td>manufacturer of  artemether/lumefantrine advises caution with darunavir </td><td></td></tr><tr><td><a href="41001i119.htm">Disopyramide</a></td><td class="cBV"><b>manufacturer of  artemether/lumefantrine advises avoid concomitant use with disopyramide (risk of ventricular arrhythmias)</b></td><td></td></tr><tr><td><a href="41001i120.htm">Flecainide</a></td><td class="cBV"><b>manufacturer of  artemether/lumefantrine advises avoid concomitant use with flecainide (risk of ventricular arrhythmias)</b></td><td></td></tr><tr><td><a href="41001i1019.htm">Fosamprenavir</a></td><td>manufacturer of  artemether/lumefantrine advises caution with fosamprenavir </td><td>Fosamprenavir is a prodrug of amprenavir</td></tr><tr><td><a href="41001i829.htm">Grapefruit Juice</a></td><td>plasma concentration of  artemether/lumefantrine possibly increased by grapefruit juice </td><td></td></tr><tr><td><a href="41001i398.htm">Indinavir</a></td><td>manufacturer of  artemether/lumefantrine advises caution with indinavir </td><td></td></tr><tr><td><a href="41001i922.htm">Lopinavir</a></td><td>manufacturer of  artemether/lumefantrine advises caution with lopinavir </td><td>In combination with ritonavir as <i>Kaletra</i>® (ritonavir is present to inhibit lopinavir metabolism and increase plasma-lopinavir concentration)—see also Ritonavir</td></tr><tr><td><a href="41001i166.htm">Macrolides</a></td><td class="cBV"><b>manufacturer of  artemether/lumefantrine advises avoid concomitant use with macrolides </b></td><td><i>See also</i> Telithromycin</td></tr><tr><td><a href="41001i451.htm">Metoprolol</a></td><td class="cBV"><b>manufacturer of  artemether/lumefantrine advises avoid concomitant use with metoprolol </b></td><td></td></tr><tr><td><a href="41001i842.htm">Nelfinavir</a></td><td>manufacturer of  artemether/lumefantrine advises caution with nelfinavir </td><td></td></tr><tr><td><a href="41001i341.htm">Quinine</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  artemether/lumefantrine given with quinine </b></td><td></td></tr><tr><td><a href="41001i193.htm">Quinolones</a></td><td class="cBV"><b>manufacturer of  artemether/lumefantrine advises avoid concomitant use with quinolones </b></td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td>manufacturer of  artemether/lumefantrine advises caution with ritonavir </td><td></td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td>manufacturer of  artemether/lumefantrine advises caution with saquinavir </td><td></td></tr><tr><td><a href="41001i455.htm">Sotalol</a></td><td class="cBV"><b>manufacturer of  artemether/lumefantrine advises avoid concomitant use with sotalol </b></td><td></td></tr><tr><td><a href="41001i1055.htm">Tipranavir</a></td><td>manufacturer of  artemether/lumefantrine advises caution with tipranavir </td><td></td></tr></tbody></table><p><b>Lumefantrine</b> belongs to
      <b>Antimalarials</b>
          but has no specific interaction information.
        </p><div>Lumefantrine interactions as for artemether with lumefantrine</div><p><b>Chloroquine and Hydroxychloroquine</b> belongs to
      <b>Antimalarials</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>















<tr><td><a href="41001i1012.htm">Agalsidase Alfa and Beta</a></td><td> chloroquine and hydroxychloroquine possibly inhibit effects of agalsidase alfa and beta (manufacturers of agalsidase alfa and beta advise avoid concomitant use)</td><td></td></tr><tr><td><a href="41001i118.htm">Amiodarone</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  chloroquine and hydroxychloroquine given with amiodarone—avoid concomitant use</b></td><td>Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</td></tr><tr><td><a href="41001i110.htm">Antacids</a></td><td>absorption of  chloroquine and hydroxychloroquine reduced by antacids </td><td>Antacids should preferably not be taken at the same time as other drugs since they may impair absorption</td></tr><tr><td><a href="41001i276.htm">Antiepileptics</a></td><td>possible increased risk of convulsions when  chloroquine and hydroxychloroquine given with antiepileptics </td><td></td></tr><tr><td><a href="41001i499.htm">Ciclosporin</a></td><td class="cBV"><b> chloroquine and hydroxychloroquine increase plasma concentration of ciclosporin (increased risk of toxicity)</b></td><td></td></tr><tr><td><a href="41001i744.htm">Cimetidine</a></td><td>metabolism of  chloroquine and hydroxychloroquine inhibited by cimetidine (increased plasma concentration)</td><td></td></tr><tr><td><a href="41001i480.htm">Digoxin</a></td><td class="cBV"><b> chloroquine and hydroxychloroquine possibly increase plasma concentration of digoxin </b></td><td></td></tr><tr><td><a href="41001i1152.htm">Droperidol</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  chloroquine and hydroxychloroquine given with droperidol—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i14.htm">Kaolin</a></td><td>absorption of  chloroquine and hydroxychloroquine reduced by kaolin </td><td></td></tr><tr><td><a href="41001i1092.htm">Lanthanum</a></td><td>absorption of   chloroquine and hydroxychloroquine possibly reduced by lanthanum (give at least 2 hours apart)</td><td></td></tr><tr><td><a href="41001i1013.htm">Laronidase</a></td><td> chloroquine and hydroxychloroquine possibly inhibit effects of laronidase (manufacturer of laronidase advises avoid concomitant use)</td><td></td></tr><tr><td><a href="41001i337.htm">Mefloquine</a></td><td class="cBV"><b>increased risk of convulsions when  chloroquine and hydroxychloroquine given with mefloquine </b></td><td></td></tr><tr><td><a href="41001i973.htm">Moxifloxacin</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  chloroquine and hydroxychloroquine given with moxifloxacin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i647.htm">Neostigmine</a></td><td> chloroquine and hydroxychloroquine have potential to increase symptoms of myasthenia gravis and thus diminish effect of neostigmine </td><td></td></tr><tr><td><a href="41001i648.htm">Pyridostigmine</a></td><td> chloroquine and hydroxychloroquine have potential to increase symptoms of myasthenia gravis and thus diminish effect of pyridostigmine </td><td></td></tr></tbody></table><p><b>Hydroxychloroquine</b> belongs to
      <b>Antimalarials</b>
          but has no specific interaction information.
        </p><div>Hydroxychloroquine interactions as for chloroquine and hydroxychloroquine</div><p><b>Mefloquine</b> belongs to
      <b>Antimalarials</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>














<tr><td><a href="41001i118.htm">Amiodarone</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  mefloquine given with amiodarone—avoid concomitant use</b></td><td>Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</td></tr><tr><td><a href="41001i276.htm">Antiepileptics</a></td><td class="cBV"><b> mefloquine antagonises anticonvulsant effect of antiepileptics </b></td><td></td></tr><tr><td><a href="41001i1009.htm">Atomoxetine</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  mefloquine given with atomoxetine </b></td><td></td></tr><tr><td><a href="41001i440.htm">Beta-blockers</a></td><td>increased risk of bradycardia when  mefloquine given with beta-blockers </td><td>Since systemic absorption may follow topical application of beta-blockers to the eye the possibility of interactions, in particular, with drugs such as verapamil should be borne in mind</td></tr><tr><td><a href="41001i466.htm">Calcium-channel Blockers</a></td><td>possible increased risk of bradycardia when  mefloquine given with calcium-channel blockers </td><td>Dihydropyridine calcium-channel blockers include amlodipine, felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, and nimodipine</td></tr><tr><td><a href="41001i335.htm">Chloroquine and Hydroxychloroquine</a></td><td class="cBV"><b>increased risk of convulsions when  mefloquine given with chloroquine and hydroxychloroquine </b></td><td></td></tr><tr><td><a href="41001i480.htm">Digoxin</a></td><td>possible increased risk of bradycardia when  mefloquine given with digoxin </td><td></td></tr><tr><td><a href="41001i387.htm">Haloperidol</a></td><td class="cBV"><b>possible increased risk of ventricular arrhythmias when  mefloquine given with haloperidol—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1050.htm">Ivabradine</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  mefloquine given with ivabradine </b></td><td></td></tr><tr><td><a href="41001i298.htm">Ketoconazole</a></td><td>plasma concentration of  mefloquine increased by ketoconazole </td><td></td></tr><tr><td><a href="41001i973.htm">Moxifloxacin</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  mefloquine given with moxifloxacin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i369.htm">Pimozide</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  mefloquine given with pimozide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i341.htm">Quinine</a></td><td class="cBV"><b>increased risk of convulsions when  mefloquine given with quinine (but should not prevent the use of <i>intravenous</i> quinine in severe cases)</b></td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td class="cBV"><b>plasma concentration of  mefloquine reduced by rifampicin—avoid concomitant use</b></td><td></td></tr></tbody></table><p><b>Primaquine</b> belongs to
      <b>Antimalarials</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i610.htm">Mepacrine</a></td><td>plasma concentration of  primaquine increased by mepacrine (increased risk of toxicity)</td><td></td></tr></tbody></table><p><b>Proguanil</b> belongs to
      <b>Antimalarials</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>



<tr><td><a href="41001i113.htm">Magnesium Salts (oral)</a></td><td>absorption of  proguanil reduced by oral magnesium salts (as magnesium trisilicate)</td><td></td></tr><tr><td><a href="41001i340.htm">Pyrimethamine</a></td><td>increased antifolate effect when  proguanil given with pyrimethamine </td><td></td></tr><tr><td><a href="41001i222.htm">Warfarin</a></td><td>isolated reports that  proguanil may enhance anticoagulant effect of warfarin </td><td></td></tr></tbody></table><p><b>Pyrimethamine</b> belongs to
      <b>Antimalarials</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>







<tr><td><a href="41001i511.htm">Methotrexate</a></td><td class="cBV"><b> pyrimethamine increases antifolate effect of methotrexate </b></td><td></td></tr><tr><td><a href="41001i1171.htm">Pemetrexed</a></td><td class="cBV"><b> pyrimethamine increases antifolate effect of pemetrexed </b></td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td class="cBV"><b> pyrimethamine antagonises anticonvulsant effect of phenytoin , also increased antifolate effect</b></td><td></td></tr><tr><td><a href="41001i339.htm">Proguanil</a></td><td>increased antifolate effect when  pyrimethamine given with proguanil </td><td></td></tr><tr><td><a href="41001i203.htm">Sulfonamides</a></td><td class="cBV"><b>increased antifolate effect when  pyrimethamine given with sulfonamides </b></td><td></td></tr><tr><td><a href="41001i217.htm">Trimethoprim</a></td><td class="cBV"><b>increased antifolate effect when  pyrimethamine given with trimethoprim </b></td><td></td></tr><tr><td><a href="41001i403.htm">Zidovudine</a></td><td>increased antifolate effect when  pyrimethamine given with zidovudine </td><td>Increased risk of toxicity with nephrotoxic and myelosuppressive drugs—for further details consult product literature</td></tr></tbody></table><p><b>Quinine</b> belongs to
      <b>Antimalarials</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>






















<tr><td><a href="41001i555.htm">Amantadine</a></td><td> quinine possibly increases plasma concentration of amantadine </td><td></td></tr><tr><td><a href="41001i118.htm">Amiodarone</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  quinine given with amiodarone—avoid concomitant use</b></td><td>Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</td></tr><tr><td><a href="41001i937.htm">Artemether with Lumefantrine</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  quinine given with artemether/lumefantrine </b></td><td></td></tr><tr><td><a href="41001i1005.htm">Atazanavir</a></td><td class="cBV"><b>plasma concentration of  quinine possibly increased by atazanavir (increased risk of toxicity)</b></td><td></td></tr><tr><td><a href="41001i744.htm">Cimetidine</a></td><td>metabolism of  quinine inhibited by cimetidine (increased plasma concentration)</td><td></td></tr><tr><td><a href="41001i1091.htm">Darunavir</a></td><td class="cBV"><b>plasma concentration of  quinine possibly increased by darunavir (increased risk of toxicity)</b></td><td></td></tr><tr><td><a href="41001i480.htm">Digoxin</a></td><td class="cBV"><b> quinine increases plasma concentration of digoxin </b></td><td></td></tr><tr><td><a href="41001i1152.htm">Droperidol</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  quinine given with droperidol—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i120.htm">Flecainide</a></td><td class="cBV"><b> quinine increases plasma concentration of flecainide </b></td><td></td></tr><tr><td><a href="41001i1019.htm">Fosamprenavir</a></td><td class="cBV"><b>plasma concentration of  quinine possibly increased by fosamprenavir (increased risk of toxicity)</b></td><td>Fosamprenavir is a prodrug of amprenavir</td></tr><tr><td><a href="41001i387.htm">Haloperidol</a></td><td class="cBV"><b>possible increased risk of ventricular arrhythmias when  quinine given with haloperidol—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i398.htm">Indinavir</a></td><td class="cBV"><b>plasma concentration of  quinine possibly increased by indinavir (increased risk of toxicity)</b></td><td></td></tr><tr><td><a href="41001i337.htm">Mefloquine</a></td><td class="cBV"><b>increased risk of convulsions when  quinine given with mefloquine (but should not prevent the use of <i>intravenous</i> quinine in severe cases)</b></td><td></td></tr><tr><td><a href="41001i973.htm">Moxifloxacin</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  quinine given with moxifloxacin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i842.htm">Nelfinavir</a></td><td class="cBV"><b>plasma concentration of  quinine possibly increased by nelfinavir (increased risk of toxicity)</b></td><td></td></tr><tr><td><a href="41001i369.htm">Pimozide</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  quinine given with pimozide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td class="cBV"><b>plasma concentration of  quinine reduced by rifampicin </b></td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>plasma concentration of  quinine increased by ritonavir (increased risk of toxicity)</b></td><td></td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  quinine given with saquinavir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i628.htm">Suxamethonium</a></td><td> quinine possibly enhances effects of suxamethonium </td><td></td></tr><tr><td><a href="41001i1055.htm">Tipranavir</a></td><td class="cBV"><b>plasma concentration of  quinine possibly increased by tipranavir (increased risk of toxicity)</b></td><td></td></tr><tr><td><a href="41001i222.htm">Warfarin</a></td><td>plasma concentration of both drugs increased when  quinine given with warfarin </td><td></td></tr></tbody></table></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_41001i937"><a href="41001i937.htm" title="Artemether with Lumefantrine">Artemether with Lumefantrine</a></li><li id="_41001i335"><a href="41001i335.htm" title="Chloroquine and Hydroxychloroquine">Chloroquine and Hydroxychloroquine</a></li><li><a href="41001i337.htm" title="Mefloquine">Mefloquine</a></li><li><a href="41001i338.htm" title="Primaquine">Primaquine</a></li><li><a href="41001i339.htm" title="Proguanil">Proguanil</a></li><li><a href="41001i340.htm" title="Pyrimethamine">Pyrimethamine</a></li><li><a href="41001i341.htm" title="Quinine">Quinine</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="41001i325.htm">Previous: Promethazine</a> | <a class="top" href="41001i334.htm#">Top</a> | <a accesskey="]" href="41001i937.htm">Next: Artemether with Lumefantrine</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>